BPC-157 + GHK-Cu

What is BPC-157 + GHK-Cu?

BPC-157 is a synthetic 15-amino-acid peptide (H-GEPPPGKPADDAGLV-OH; free-base MW ~1,419.5 g/mol). Acetate-containing material is not mass-equivalent to free base unless the assay reports peptide-equivalent content.

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine (Copper Tripeptide-1). GHK alone and GHK-Cu are not interchangeable. The combination is a two-component mixture — not a conjugate, salt, or single active ingredient.

A label stating only “60 mg blend” is incomplete because it does not establish how much of each component is present.

Common 60 mg composition

The 50/10 mg configuration is commercially documented but not pharmacologically standardized. Some sellers offer different strengths. Independent quantitative assay should confirm both component amounts.

Using a representative GHK-Cu MW of 401.91 g/mol, copper accounts for approximately 15.81% of complex mass (~158 mcg Cu per 1 mg GHK-Cu). This is compositional math — not bioavailability.

Identity and label checks

GHK versus GHK-Cu: GHK is the copper-free ligand; GHK-Cu is the copper complex. Blue color is consistent with coordination but cannot establish identity, ratio, potency, sterility, or endotoxin status alone.

Confirm the product is not GLOW (adds TB-500), KLOW (adds KPV+TB-500), KPV+GHK-Cu (KPV replaces BPC-157), or Wolverine Stack (BPC-157 + TB-500 without GHK-Cu).

U.S. medicinal and research status

There is no U.S. prescribing label or standardized medicinal dosage for the fixed BPC-157 + GHK-Cu combination. FDA reviewed BPC-157 bulk-drug-substance information in 2026 and discussed substantial gaps involving characterization, impurities, aggregation, immunogenicity, sterility, endotoxin, and stability.

GHK-Cu is widely used topically as Copper Tripeptide-1. Cosmetic use does not establish the safety, pharmacokinetics, or dosage of an injectable GHK-Cu product.

Available 50/10 mg schedules are community conventions — not approved prescribing protocols.

Has the exact BPC-157 + GHK-Cu combination been studied?

No controlled human or animal study of the exact 50 mg GHK-Cu + 10 mg BPC-157 blend was identified. A 2026 narrative review considered BPC-157 and GHK-Cu in parallel and identified combined protocols as a future research priority — that is not evidence the combination has been tested or produces synergy.

To test synergy, a study would need at least four comparable groups (control, BPC-157 alone, GHK-Cu alone, combination) with prespecified doses, the same route and schedule, and interaction analysis.

Human research dosages: exact combination vs component studies

Exact combination: No human dose has been studied for the BPC-157 + GHK-Cu pair.

BPC-157: Isolated research exposures include intra-articular knee injection, bladder-wall cystoscopy series, two-person IV pilot, registered oral Phase 1, and registered SC hamstring-injury study — different tissues, routes, and designs that do not converge on a validated systemic dose.

GHK-Cu: Human research is mainly topical (diabetic neuropathic ulcers, post-CO₂-laser skin care, cosmetic photoaging, registered punch-wound Phase 2). No controlled injectable human GHK-Cu dose-ranging study was located.

Reported BPC-157 + GHK-Cu dosage range

The following ranges summarize community and commercial research conventions. They are not clinically established. A report that says only “10 units” or “20 units” is not a dosage — vial composition and final volume are required.

Complete fixed-exposure research protocol

This protocol documents the most traceable 50 mg/10 mg community convention as an observational research template — not a prescribing recommendation. It deliberately uses a fixed exposure (no automatic titration) so outcome and adverse-event data remain interpretable.

Assumes a 50/10 mg vial prepared to 3.0 mL (20 mg/mL total). One U-100 unit = 0.01 mL = 200 mcg total blend (≈166.7 mcg GHK-Cu + 33.3 mcg BPC-157). Two 50/10 mg vials are required before handling loss (one vial = 25 complete 0.12 mL exposures).

Stopping rules: suspected anaphylaxis; infection signs; severe local reaction; chest pain, SOB, neurologic deficit; lab abnormality; product-quality failure; pregnancy; serious AE pattern. Rechallenge after serious events requires qualified oversight.

Vial inventory: 100.8 mg nominal six-week cycle = 1.68 reference vials → two 60 mg vials before handling loss. Second vial begins day 26 if every exposure is completed.

Reconstitution math for a 50 mg/10 mg vial

These tables assume 50 mg GHK-Cu + 10 mg BPC-157 = 60 mg total, accurate 5:1 ratio, and final volume (not simply liquid added). U-100 syringe: 1 unit = 0.01 mL. Always calculate both components — a correct total-blend calculation can hide an incorrect ratio.

Universal formula: Component dose (mg) = concentration (mg/mL) × volume (mL). For U-100: volume (mL) = units ÷ 100.

Why fixed-ratio blends are difficult to study

A 50/10 mg vial locks GHK-Cu and BPC-157 into a 5:1 mass ratio. Every volume change moves both components together — a lower BPC-157 exposure automatically lowers GHK-Cu, and adverse events cannot be assigned confidently to one component.

Independent component vials are analytically cleaner for formal dose-ranging and factorial research. That does not establish that either product is suitable for human use.

Anecdotal versus clinically studied dosing

Preclinical component dosages

BPC-157 animal research spans tendon, muscle, ligament, GI, vascular, and neurologic models. A frequently encountered rodent exposure is ~10 mcg/kg/day IP or oral — route, injury model, and product identity vary. Simple body-weight conversion is not dose validation.

GHK-Cu cell and animal research uses heterogeneous topical concentrations and local delivery. Findings involving collagen, ECM, antioxidant signaling, and angiogenesis are mechanistic — they do not establish a systemic human dose.

No direct preclinical bridge exists for the combination: no evidence-based method to select starting ratio, NOAEL, MTD, route-specific safety margin, or human-equivalent combination dose.

How might BPC-157 and GHK-Cu work?

BPC-157 preclinical work associates fibroblast migration, VEGFR2/Akt/eNOS pathways, angiogenesis, and tendon/ligament/muscle/GI repair models with inflammatory and oxidative-stress modulation.

GHK-Cu laboratory and topical research associates copper transport, collagen/elastin remodeling, MMP/TIMP balance, antioxidant signaling, and keratinocyte/wound activity.

It is biologically plausible the components affect overlapping tissue-remodeling stages. Plausibility is not proof — overlapping activity can produce additivity, redundancy, antagonism, or additional risk. No controlled interaction analysis has shown synergy.

What results are reported, and when?

Visible skin change, pain reduction, and structural healing are different outcomes. A lower pain score does not prove tendon repair. Photographs without consistent lighting, scale, and blinded evaluation are weak evidence.

Route of administration

Common claims vs evidence

Evidence ladder

The exact blend remains at the bottom of the dosage-evidence hierarchy. A more precise syringe-unit table improves reproducibility; it does not raise the clinical evidence level.

BPC-157 + GHK-Cu vs GLOW and KLOW blends

Safety and adverse effects

Very little controlled data exist for the exact combination: acute/chronic toxicity, PK, interaction, MTD, reproductive effects, genotoxicity, immunogenicity, long-term copper handling, and repeat-cycle exposure are all unestablished.

Commonly reported local effects in community GHK-Cu-containing injection reports include burning, stinging, redness, itching, swelling, welts, bruising, tenderness, and persistent nodules — incidence unknown.

Storage and stability

For a co-formulated 50/10 mg blend, a useful stability program should measure BPC-157 identity/potency, GHK-Cu identity/potency/copper occupancy, free copper, component ratio, aggregation, pH, particulates, container-closure integrity, and microbial control through the intended in-use period.

Discard when the validated in-use period ends, container integrity is lost, unexpected cloudiness/precipitation/particulates/color change occurs, storage cannot be verified, or label/lot/reconstitution records are missing.

WADA and tested sport

The 2026 WADA Prohibited List places BPC-157 in section S0, Non-Approved Substances, prohibited at all times. Because the blend contains BPC-157, it is incompatible with drug-tested sport regardless of whether GHK-Cu is separately named.

Bottom line

BPC-157 + GHK-Cu is a two-component research blend with a common commercial composition of 50 mg GHK-Cu plus 10 mg BPC-157. The most reproducible community convention brings that vial to 3.0 mL and records 12 U-100 units as 2 mg GHK-Cu plus 400 mcg BPC-157 once daily for 6 weeks, followed by 2–3 weeks without exposure.

That precision describes the arithmetic — not the strength of the evidence. No controlled combination study has established a therapeutic dosage, optimal ratio, injectable GHK-Cu exposure, interaction profile, or synergy. The most defensible research approach keeps the two identities separate, verifies each component analytically, uses a fixed protocol with prospective outcomes and stopping rules, and does not transfer topical GHK-Cu or single-agent BPC-157 findings to the blend.

Confirm vial ratio, GHK-Cu copper occupancy, BPC-157 free-base vs acetate reporting, theoretical copper exposure, and mixed-vial stability — before trusting any unit chart.

Frequently asked questions

References

• Wojcieszuk O et al.

  BPC-157 and GHK-Cu in Wound Healing and Tissue Repair: A Review

  2026 narrative review — parallel molecules, not exact blend trial.

• FDA

  Pharmacy Compounding Advisory Committee: BPC-157 evaluation

  2026 chemistry and safety gaps review.

• Pickart L, Margolina A.

  Regenerative and Protective Actions of GHK-Cu

  2018 — topical/lab context.

• Mulder GD et al.

  Topical GHK-Cu in diabetic neuropathic ulcers

  1994 — not injectable blend dosing.

• Lee E et al.

  Intra-articular BPC-157 for knee pain: retrospective chart review

  BPC-only; not blend evidence.

• ClinicalTrials.gov

  GHK-Cu gel punch wounds NCT07437586

  Topical wound trial — no injectable dose.

• WADA

  2026 Prohibited List

  BPC-157 S0 — prohibited at all times.